These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 8671503)

  • 21. Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus intramuscular progesterone.
    Claman P; Domingo M; Leader A
    Hum Reprod; 1992 Apr; 7(4):487-9. PubMed ID: 1522190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients.
    Martazanova B; Mishieva N; Vedikhina I; Kirillova A; Korneeva I; Ivanets T; Abubakirov A; Sukhikh GT
    Front Endocrinol (Lausanne); 2022; 13():834627. PubMed ID: 36046787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
    Olivennes F
    J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The benefit of individualized low-dose hCG support for high responders in GnRHa-triggered IVF/ICSI cycles.
    Huang CY; Shieh ML; Li HY
    J Chin Med Assoc; 2016 Jul; 79(7):387-93. PubMed ID: 27147462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin-releasing hormone agonist/menotrophin in-vitro fertilization cycles.
    Golan A; Herman A; Soffer Y; Bukovsky I; Caspi E; Ron-El R
    Hum Reprod; 1993 Sep; 8(9):1372-5. PubMed ID: 8253920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effect of exogenous human chorionic gonadotrophin on progesterone production from normal or malfunctioning corpus luteum.
    Momoeda M; Tsutsumi O; Morita Y; Igarashi T; Suenaga A; Osuga Y; Shiotsu H; Yano T; Taketani Y
    Hum Reprod; 1998 Jul; 13(7):1907-11. PubMed ID: 9740447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The exogenous progesterone-free luteal phase: two pilot randomized controlled trials in IVF patients.
    Humaidan P; Alsbjerg B; Elbaek HO; Povlsen BB; Laursen RJ; Jensen MB; Mikkelsen AT; Thomsen LH; Kol S; Haahr T
    Reprod Biomed Online; 2021 Jun; 42(6):1108-1118. PubMed ID: 33931371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study.
    Humaidan P; Bungum L; Bungum M; Yding Andersen C
    Reprod Biomed Online; 2006 Aug; 13(2):173-8. PubMed ID: 16895629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luteal phase support in in vitro fertilization.
    Yanushpolsky EH
    Semin Reprod Med; 2015 Mar; 33(2):118-27. PubMed ID: 25734349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active corpus luteum function at pre-, peri- and postimplantation is essential for a viable pregnancy.
    Liu HC; Pyrgiotis E; Davis O; Rosenwaks Z
    Early Pregnancy; 1995 Dec; 1(4):281-7. PubMed ID: 9363260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study.
    Lewit N; Kol S; Manor D; Itskovitz-Eldor J
    Hum Reprod; 1996 Jul; 11(7):1399-402. PubMed ID: 8671474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of luteal HCG supplementation in GnRH-agonist-triggered fresh embryo transfer cycles: a randomized controlled trial.
    Svenstrup L; Möller S; Fedder J; Pedersen DE; Erb K; Andersen CY; Humaidan P
    Reprod Biomed Online; 2024 May; 48(5):103415. PubMed ID: 38452605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles.
    Farhi J; Weissman A; Steinfeld Z; Shorer M; Nahum H; Levran D
    Fertil Steril; 2000 Apr; 73(4):761-6. PubMed ID: 10731538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.